November 17, 2023 12:21 PM EST
Pharma
FDA+

Mer­ck notch­es 38th ap­proval for Keytru­da, sev­enth in­di­ca­tion for gas­troin­testi­nal can­cer

Lia DeGroot

The FDA on Thurs­day ap­proved Mer­ck’s an­ti-PD-1 ther­a­py to treat a type of gas­troin­testi­nal can­cer in com­bi­na­tion with chemother­a­py, mark­ing the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Roche’s Parkin­son’s drug flunks sec­ond mid-stage tri­al

David Ep­stein gets $140M for Ot­ti­mo's bi­func­tion­al take on hot PD-1xVEGF field

Sang­amo strikes an­oth­er brain-tar­get­ing AAV part­ner­ship, this time with Astel­las

Bris­tol My­ers pays $100M up­front to col­lab­o­rate with Leqem­bi orig­i­na­tor in Alzheimer's

A service from the Financial Times